Neuropathic and neurodegenerative diseases represent a broad and growing global health crisis
- $800B annual economic burden in the U.S.
- 1 in 4 people worldwide experience vision impairment
- Over 1 in 3 people are affected by neurological diseases, the leading cause of illness and disability worldwide
- Diabetes was responsible for 3.4 million deaths in 2024 – 1 every 9 seconds
Yet no treatments exist to modify or halt these diseases, highlighting huge need for novel solutions.
On track to begin clinical trials
Advancing towards human clinical trials through IND-enabling studies.
Breakthrough nerve regeneration through promotion of nerve growth factor and neuroplasticity. Extremely potent at small concentrations of drugs. Huge potential across therapeutic areas and diseases.
4 IND enabling development programs experience and 10 clinical trials run. Ex-Alcon and big pharma. Launched 2A Biosciences’ ophthalmology program.
Raised $5.25M from leading psychedelic investors and family offices.
Established company with co-founders Dr. Charles Nichols, Dr. David Nichols, Dr. Timothy Foster, and Alex Speiser.
Dr. David Nichols defined serotonin 2A receptors’ therapeutic role in psychiatry, publishing the first paper on MDMA, and responsible for psychedelic IP being used in the clinic today (i.e. Compass Pathways).
Charles discovered 2A activation drives potent anti-inflammatory effects in asthma, cardiovascular, and autoimmune disease models, building upon his earlier efficacy work in models of neuropsychology.
With Dr. Timothy Foster, they confirmed 2A’s therapeutic impact in further inflammatory, ocular, and neurodegenerative disease models.
